Gsk (GLAXF) Dividends Paid - Common Growth (1y) (2010 - 2026)
Gsk (GLAXF) Dividends Paid - Common Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Div. Paid (Common) Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-12.46% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
15.01% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
4.75% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
5.50% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
2.68% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
6.18% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
3.59% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
0.33% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
1.99% |
| 10 |
Gsk |
- |
- |
7.76 Bn |
-12.46% |
| Date | Value |
|---|
| Mar 31, 2026 |
-12.46% |
| Dec 31, 2025 |
-216.57% |
| Sep 30, 2025 |
-28.52% |
| Jun 30, 2025 |
-16.16% |
| Mar 31, 2025 |
-6.98% |
| Dec 31, 2024 |
-69.70% |
| Sep 30, 2024 |
-43.96% |
| Jun 30, 2024 |
18.28% |
| Mar 31, 2024 |
-6.81% |
| Dec 31, 2023 |
-101.60% |
| Sep 30, 2023 |
71.24% |
| Mar 31, 2023 |
47.19% |
| Dec 31, 2022 |
1,976.03% |
| Sep 30, 2022 |
-58.34% |
| Mar 31, 2022 |
2.07% |
| Dec 31, 2021 |
79.80% |
| Sep 30, 2021 |
93.99% |
| Jun 30, 2021 |
82.26% |
| Mar 31, 2021 |
-8.14% |
| Dec 31, 2020 |
40.12% |
